MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®. “The agreement is part of our international commercialization of Emtrix®. As the leading Italian pharmaceutical group, ranked 34th in the world, Menarini is well positioned to make Emtrix® a success in Italy. Emtrix® will now be marketed in all large markets in Europe, in US and Australia”, says Peter Wolpert, President and CEO of Moberg Derma. About Emtrix® and nail disease Emtrix® is a topical treatment used to treat nail disease. Launched in the Nordic region in autumn 2010, it quickly became market leader. Emtrix® is a prescription free, over-the-counter product sold under the name Nalox™ in certain markets and under the name Kerasal® Nail in the U.S. Safety and efficacy have been demonstrated in several clinical studies including more than 600 patients. Emtrix® has a unique and rapid mechanism of action which brings visible improvements within 2-4 weeks of treatment. Nail fungus is the most common nail disease and afflicts approximately 10% of the general population and increasing with age. The estimated global market potential exceeds USD 1 billion. The untapped potential is significant since many patients remain untreated. It is generally recognized that there is a need for new efficacious and safe topical treatments. About this information Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am (CET) on December 9th, 2011. For further information, please contact: Peter Wolpert, President and CEO Telephone: 46 8 522 307 00 Mobile: 46 735 71 35 E-mail: peter.wolpert@mobergderma.se Magnus Persson, IR Mobile: 46 73-355 26 01 E-mail: magnus.persson@mobergderma.se
MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY
| Source: Moberg Pharma AB